TY - JOUR
T1 - Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer
AU - Medeiros, Mariana Silva
AU - Botelho de Carvalho, Luís André
AU - Alves, Marta
AU - Papoila, Ana
AU - Baptista Carreira dos Santos, Hugo Miguel
AU - Capelo-Martínez, José Luis
AU - Pinheiro, Luís Manuel Viegas de Campos
N1 - Publisher Copyright:
© The Author(s) 2024.
Open access funding provided by FCT|FCCN (b-on).
PY - 2024/8
Y1 - 2024/8
N2 - Purpose: T1 bladder cancer is known for its high progression and recurrence rates. Identifying aggressive tumours at the non-muscle-invasive stage is crucial to allow early interventions and subsequently increase patient survival. This study aimed to investigate the potential of the cubilin/myeloperoxidase (CUBN/MPO) ratio as a high-grade T1 bladder cancer biomarker. Methods: Urine samples were collected from 30 patients who underwent transurethral resection of the tumour with high-grade T1 bladder cancer (June 2015 to December 2019) before surgery. The urinary proteome was analysed using high-resolution mass spectrometry and the CUBN/MPO ratio was calculated. The primary outcome was the recurrence during the follow-up (around 31.5 months after resection). Univariate Cox regression and Kaplan–Meier curves were used for data analysis. Results: Patients with a low CUBN/MPO ratio exhibited upregulated MPO and/or downregulated CUBN. This group of patients had a higher incidence of disease recurrence and progression. Low CUBN/MPO ratio was significantly associated with a higher likelihood of recurrence, progression, and death. It is worth noting that this study was exploratory and conducted on a small sample size, so further research is needed to validate these findings in larger cohorts. Conclusion: This study highlights the potential of the CUBN/MPO ratio as a prognostic biomarker for high-grade T1 bladder cancer.
AB - Purpose: T1 bladder cancer is known for its high progression and recurrence rates. Identifying aggressive tumours at the non-muscle-invasive stage is crucial to allow early interventions and subsequently increase patient survival. This study aimed to investigate the potential of the cubilin/myeloperoxidase (CUBN/MPO) ratio as a high-grade T1 bladder cancer biomarker. Methods: Urine samples were collected from 30 patients who underwent transurethral resection of the tumour with high-grade T1 bladder cancer (June 2015 to December 2019) before surgery. The urinary proteome was analysed using high-resolution mass spectrometry and the CUBN/MPO ratio was calculated. The primary outcome was the recurrence during the follow-up (around 31.5 months after resection). Univariate Cox regression and Kaplan–Meier curves were used for data analysis. Results: Patients with a low CUBN/MPO ratio exhibited upregulated MPO and/or downregulated CUBN. This group of patients had a higher incidence of disease recurrence and progression. Low CUBN/MPO ratio was significantly associated with a higher likelihood of recurrence, progression, and death. It is worth noting that this study was exploratory and conducted on a small sample size, so further research is needed to validate these findings in larger cohorts. Conclusion: This study highlights the potential of the CUBN/MPO ratio as a prognostic biomarker for high-grade T1 bladder cancer.
KW - CUBN/MPO
KW - Non-muscle-invasive bladder cancer
KW - Recurrence
KW - Urinary proteome
UR - http://www.scopus.com/inward/record.url?scp=85188991914&partnerID=8YFLogxK
U2 - 10.1007/s11255-024-03971-4
DO - 10.1007/s11255-024-03971-4
M3 - Article
C2 - 38530585
AN - SCOPUS:85188991914
SN - 0301-1623
VL - 56
SP - 2577
EP - 2587
JO - INTERNATIONAL UROLOGY AND NEPHROLOGY
JF - INTERNATIONAL UROLOGY AND NEPHROLOGY
ER -